Evaluation of sputum eosinophil count as a predictor of treatment response to mepolizumab.

Ian D PavordRoland BuhlMonica KraftCharlene M PrazmaRobert G Price Peter J HowarthSteven W Yancey

Published in: ERJ open research (2022)

In patients with severe eosinophilic asthma and sputum eosinophil counts of ≥3-<30%, sputum eosinophils may not represent a more useful biomarker than blood eosinophils for predicting clinical treatment response to mepolizumab https://bit.ly/3pOTw93.

Keyphrases

cystic fibrosis
mycobacterium tuberculosis
pulmonary tuberculosis
chronic obstructive pulmonary disease
peripheral blood
early onset
lung function
combination therapy
chronic rhinosinusitis